Atropine Eye Ointment, Eye Drops, Injection, Ophthalmic, Injectable Solution, Intramuscular Solution, Intravenous Solution, Oral

Atropine, a tertiary amine antimuscarinic, produces dilation and loss of accommodation by blocking the response of iris sphincter muscle and the accommodative ciliary muscle to cholinergic stimulation.


Atropine Hydrobromide sterile Eye Drops is used for use as a mydriatic and cycloplegic agent.

Atropine is also used to associated treatment for these conditions: Strabismus

Trade Name Atropine
Generic Homatropine
Other Names Homatropina, Omatropina
Weight 0.6mg/ml, 1 mg/ml, 1%, , 1%w/w, 1%w/v, 0.05mg/ml, 0.1mg/ml, 0.4mg/ml, 0.4mg/ml + nacl0.9%, 1mg/ml, 2mg/0.7ml, 025mg/ml
Type Eye Ointment, Eye Drops, Injection, Ophthalmic, Injectable Solution, Intramuscular Solution, Intravenous Solution, Oral
Formula C16H21NO3
Weight Average: 275.348
Monoisotopic: 275.15214354
Protein binding

No pharmacokinetic data available.

Therapeutic Class Mydriatic and Cycloplegic agents
Manufacturer Jawa Pharmaceutical Pvt Ltd, Pharmatak Opthalmics I Pvt Ltd, Chemist Laboratories Limited, Jayson Pharma Ltd, Edruc Ltd, Essential Drugs Company Ltd, Opso Saline Ltd, Kdh Laboratories Ltd, Lahore Chemical & Pharmaceutical Works (pvt) Ltd, Pt Ethica
Available Country India, Bangladesh, Australia, Pakistan, United States, Indonesia, Switzerland
Last Updated: June 23, 2021 at 9:10 am


Atropine dosage

Mydriasis and cycloplegia for refraction:

  • Adult: Instill 1 or 2 drops of 2% solution, or 1 drop of 5% solution immediately before the procedure, repeat at 5-10 minute intervals if necessary.
  • Child: Instill 1 drop of 2% soln immediately before the procedure, repeat at 10-min intervals if necessary.


  • Adult: Instill 1-2 drops of 2% or 5% solution bid-tid up to every 3-4 hr as needed.
  • Child: 3 mth- 2 yr: instill 1 drop of 0.5% soln once daily or on alternate days. >2 yr: instill 1 drop of 1% or 2% soln bid.

Side Effects

Hypersensitivity may occur as conjunctivitis.


Should be used with caution in patients with prostatic enlargement and in patients suffering from paralytic ileus or pyloric stenosis.


Effects may be increased by drugs with antimuscarinic effect such as; some antihistamines; phenothiazines; antipsychotics; TCAs; MAOIs or parasympathomimetics.

Food Interaction

No interactions found.

Volume of Distribution

No pharmacokinetic data available.

Half Life

No pharmacokinetic data available.


No pharmacokinetic data available.

Pregnancy & Breastfeeding use

Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. Matropin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 

Use in lactation: It is not known whether Atropine is excreted in human milk. Caution should be exercised when Matropin is administered to a nursing mother.


Contraindicated in patients with closed-angle glaucoma or with a narrow angle between the iris and the cornea.

Special Warning

Use in children: Should not be used in children below the age of 3 months

Acute Overdose

Ataxia, incoherent speech, restlessness, hallucinations, disorientation, failure to recognize people and tachycardia. Psychotic reactions and behavioural disturbances (in children). SC/IM/IV Physostigmine salicylate 1-2 mg to control central and peripheral effects. Small doses of short-acting barbiturate eg. thiopentone sodium 100 mg to control excitement.

Atropine contains Homatropine see full prescribing information from innovator Monograph